Piper Sandler analyst Matthew O’Brien reiterated a Buy rating on Tandem Diabetes Care (TNDM – Research Report) today and set a price target of $35.00. The company’s shares closed yesterday at $22.55.
O’Brien covers the Healthcare sector, focusing on stocks such as Sight Sciences, Atricure, and Medtronic. According to TipRanks, O’Brien has an average return of 6.7% and a 52.36% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Tandem Diabetes Care with a $30.75 average price target, implying a 36.36% upside from current levels. In a report released today, TD Cowen also maintained a Buy rating on the stock with a $35.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $44.85 and a one-year low of $13.82. Currently, Tandem Diabetes Care has an average volume of 1.46M.
Based on the recent corporate insider activity of 101 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TNDM in relation to earlier this year. Last month, Rajwant Sodhi, a Director at TNDM bought 1,070.00 shares for a total of $29,596.20.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care (TNDM) Company Description:
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.
Read More on TNDM:
